Freedom Capital Markets initiated coverage on Doximity Inc. (NYSE: DOCS) with a Buy rating and a $31 price target, highlighting the company’s strong growth potential and network effects.
The firm valued the company at approximately 7x its 2027 enterprise value to revenue and 14x EBITDA.
Freedom Capital described Doximity as more than just a professional networking platform for physicians, noting its role as a comprehensive digital ecosystem where healthcare professionals collaborate, access content, manage clinical workflows, and practice medicine.
The analyst emphasized the platform’s high user engagement and strong network effects, which are expected to support above-average growth and significant operating leverage as the business scales.
However, the firm acknowledged competitive pressures from a fragmented landscape of specialized point solutions offering “best-of-breed” functionality.
Despite these challenges, Freedom Capital believes the recent decline in the stock price presents an attractive entry point, with potential upside of approximately 25%.
The firm also noted risks related to pharmaceutical advertising spending trends and the emergence of a notable competitor but maintained that the risk-reward profile remains favorable.
